Phase II trial of topotecan in malignant melanoma

Cancer Investigation

Volumn 15, Issue 4, 1997, Pages 318-320

  Kraut, Eric H ^a,b   Walker, Michael J ^a   Staubus, Al ^a   Gochnour, Diane ^a   Balcerzak, Stanley P ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b 10 North Doan Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; GLYCOPROTEIN P; TOPOTECAN;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MECHANISM; FEMALE; GRANULOCYTE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; MALE; MELANOMA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN METASTASIS; SOFT TISSUE TUMOR; THROMBOCYTE COUNT; VOMITING;

EID: 0030847834     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909709039732     Document Type: Article

References (6)

1. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufman SH: The current status of camptothecin analogies as antilumor agents. J Natl Cancer Inst 85:271-289, 1993.
2. D'arpa P, Liu LF: Topoisomerase targeting antitumor drugs. Biochim Biophys Acta 989:163-177, 1989.
3. Tanizawa A, Fujimori A, Pommier Y: A comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86:836-842, 1994.
4. Hsiang Y, Liu LF, Wall ME, Wani MC, Nicholas A, Manikumar G, Kirschenbaum S, Silber R, Potmesil M: DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49:4835-4839, 1989.
5. Baleh CM, Houghton AN, Peters LJ, de Vita V: Cutaneous melanoma. In: Cancer Principles and Practice of Oncology, 4th ed, Philadelphia, Lippincott JB, 1993, pp 1639-1940.
6. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SG, Lubejko BG, Kaufman SH, Donehower RC: Phase I and pharmacologic study of topotecan, a novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992.